AMGN compared with SABS: revenue, margins and what each company keeps, and the suppliers and customers both name

AMGNAmgen Inc

Mkt capRevenueRevenue

SABSSAB Biotherapeutics, Inc.

Mkt capRevenueRevenue

Compare

AMGNAmgen Inc

SABSSAB Biotherapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only AMGN 12

PODDInsuletsupplier

CYTKCytokineticssupplier

ARWRArrowhead Pharmaceuticalssupplier

LGNDLigand Pharmaceuticalssupplier

8 more · AMGN chain ›

Shared 0

No shared counterparties.

Only SABS 5

EBSEmergent BioSolutions Canadasupplier

—Avance Clinical PTY, Ltd ("Avance")unlistedsupplier

—Fortrea Holdings Inc. ("Fortrea")unlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

—

Sanford Applied Biosciences

unlistedsupplier

1 more · SABS chain ›

AMGNAmgen Inc

460.55▲+0.06%· post 460.42

Mkt cap$249.0BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

SABSSAB Biotherapeutics, Inc.

3.02▲+2.59%· post 3.02

ClosedNov 6 '26

Mkt cap$273.0MRevenue$114,698Q4 FY24Revenue—

Compare

ClosedNov 6 '26

AMGNAmgen Inc

SABSSAB Biotherapeutics, Inc.

460.55▲+0.06%post 460.42

Price

3.02▲+2.59%post 3.02

$249.0B

Mkt cap

$273.0M

Q3 FY26$10.4B

Revenue

$114,698Q4 FY24

FY25$36.8B

Revenue

—

AMGN460.55▲+0.06%vsSABS3.02▲+2.59%ClosedNov 6 '26